Nelson's syndrome: a review of the clinical manifestations, pathophysiology, and treatment strategies.

Abstract

Nelson's syndrome is a rare clinical manifestation that occurs in 8%-47% of patients as a complication of bilateral adrenalectomy, a procedure that is used to control hypercortisolism in patients with Cushing's disease. First described in 1958 by Dr. Don Nelson, the disease has since become associated with a clinical triad of hyperpigmentation, excessive adrenocorticotropin secretion, and a corticotroph adenoma. Even so, for the past several years the diagnostic criteria and management of Nelson's syndrome have been inadequately studied. The primary treatment for Nelson's syndrome is transsphenoidal surgery. Other stand-alone therapies, which in many cases have been used as adjuvant treatments with surgery, include radiotherapy, radiosurgery, and pharmacotherapy. Prophylactic radiotherapy at the time of bilateral adrenalectomy can prevent Nelson's syndrome (protective effect). The most promising pharmacological agents are temozolomide, octreotide, and pasireotide, but these agents are often administered after transsphenoidal surgery. In murine models, rosiglitazone has shown some efficacy, but these results have not yet been found in human studies. In this article, the authors review the clinical manifestations, pathophysiology, diagnostic criteria, and efficacy of multimodal treatment strategies for Nelson's syndrome.

• Authors: Jimmy Patel, Jean Anderson Eloy, James K Liu
• Journal: Neurosurgical focus (Neurosurg Focus) Vol. 38 Issue 2 Pg. E14 (Feb 2015) ISSN: 1092-0684 [Electronic] United States
• PMID: 25639316 (Publication Type: Journal Article, Review)

Chemical References

• Somatostatin

Topics

• Adrenalectomy (adverse effects)
• Combined Modality Therapy (methods)
• Humans
• Nelson Syndrome (diagnosis, physiopathology, therapy)
• Pituitary ACTH Hypersecretion (diagnosis, surgery)
• Somatostatin (analogs & derivatives, therapeutic use)